![](https://www.netfarma.pt/wp-content/uploads/Medicamentos-22-600x400.jpg)
![](https://www.netfarma.pt/wp-content/uploads/Medicamentos-22-600x400.jpg)
![](https://www.netfarma.pt/wp-content/uploads/brystol-myers-squibb-600x400.png)
Bristol Myers Squibb nomeia Juan Carlos Portasany como novo Diretor Comercial em Portugal
![](https://www.netfarma.pt/wp-content/uploads/D9Bt2o7WsAIbpJC-600x400.jpg)
Empliciti com parecer positivo aguarda recomendação
![](https://www.netfarma.pt/wp-content/uploads/industria-1-600x400.png)
Bristol-Myers Squibb chega a acordo para adquirir Celgene por 65 mil milhões de euros
![](https://www.netfarma.pt/wp-content/uploads/2017/12/cdd6d778cbfe375c3910c441ad66bcb9-600x355.jpg)
Bristol-Myers Squibb: INFARMED autoriza terapêutica para melanoma avançado e cancro do pulmão
![](https://www.netfarma.pt/wp-content/uploads/2018/05/0d1e97e9e4fb82807a79eb4e2d389a98.jpg)
FDA atribui Biologics License Application a medicamento da Bristol-Myers Squibb
![](https://www.netfarma.pt/wp-content/uploads/2018/05/0d1e97e9e4fb82807a79eb4e2d389a98.jpg)
Cancro da bexiga: FDA considera tratamento da Bristol-Myers Squibb “breakthrough therapy”
![](https://www.netfarma.pt/wp-content/uploads/2018/05/3fc9c17d63ef6cb9aeb00c8219f3f061.jpg)
CE aprova combinação entre agentes de imuno-oncologia da Bristol-Myers Squibb
![](https://www.netfarma.pt/wp-content/uploads/2018/05/c6ce282e2c635b0b6a77f23985c425aa.jpg)
CHMP recomenda alargamento da indicação do Opvido da Bristol-Myers Squibb
![](https://www.netfarma.pt/wp-content/uploads/2018/05/0d1e97e9e4fb82807a79eb4e2d389a98.jpg)